GMP IPO Watch
Sai Parenteral’s IPO: Pharma’s Global Export Story Bids Tomorrow—Is it Worth the Premium?
Hyderabad-based Sai Parenteral's Limited enters the mainboard market on March 24, 2026, with a price band of ₹372–₹392. Specializing in sterile injectables and high-end formulations, the company is using this IPO to fund a major Australian acquisition and a new R&D center. We break down the ₹0 GMP, the 72x valuation, and the risks you should know.
Live IPO tracking available
Check GMP movement, allotment details, subscription demand, and deeper IPO context for this company.
Use these shortcuts to keep exploring
The archive button opens all articles from this category. The IPO details button opens the live IPO page on your GMP site in a new tab.
1. Today’s Big Move: The Anchor Allotment
Before the retail public gets a chance tomorrow, institutional "anchor" investors are placing their bids today, March 23.
The Goal: The company is looking to lock in a significant portion of its ₹409 crore goal from big funds today.
What to watch: If we see top-tier domestic mutual funds or global insurance players joining the anchor list, it will provide a much-needed confidence boost for the public opening tomorrow.
2. The "Sterling" Portfolio: What do they do?
Sai Parenteral's isn't just a local pharmacy supplier. They are a high-tech manufacturer of injectables (which contribute over 44% of their revenue) and other complex dosage forms like tablets and ointments.
Global Footprint: They recently acquired a majority stake in Noumed Pharmaceuticals (Australia), giving them direct access to the Australian and New Zealand markets.
Therapeutic Range: They cover everything from cardiovascular and anti-diabetic meds to neuropsychiatry and dermatology.
3. Grey Market Pulse: A "Flat" Signal
Current GMP: ₹0 (as of midday today).
Estimated Listing: ₹392 (0% gain).
Interpretation: Currently, the grey market is showing "zero" excitement. This often happens when a stock is priced "to perfection" or when the broader market (Nifty/Sensex) is under pressure. This is likely a stock for people who believe in the company's 3-year growth plan rather than those looking for a quick "listing day" flip.
4. IPO Timeline & Application Guide
| Event / Detail | Information |
|---|---|
| IPO Opens for Public | Tomorrow, Tuesday, March 24, 2026 |
| IPO Closes | Friday, March 27, 2026 |
| Price Band | ₹372 to ₹392 per share |
| Minimum Lot Size | 38 Shares |
| Retail Min. Investment | ₹14,896 |
| Listing Date | Thursday, April 2, 2026 |
5. Financial Snapshot: Growth vs. Valuation
The Growth: Revenue grew at a healthy 3-year CAGR of ~30%, with profits jumping to ₹14.45 crore in FY25.
The Valuation: At the upper price of ₹392, the company is asking for a P/E ratio of ~72x.
Peer Check: For context, peers like Innova Captab trade around 32x, while Sai Life Sciences (a larger player) trades at over 100x. Sai Parenteral's is definitely positioned as a "premium" priced issue.
6. The "Reality Check": Risks to Consider
Regulatory Red Flags: As of late 2025, the company faced two blacklisting orders from state health agencies regarding product quality. While they are contesting these in court, a negative outcome could hurt their ability to win government tenders.
Manufacturing Pause: They plan to shut down two major units in Hyderabad for ~6 months to upgrade them using IPO funds. This could lead to a temporary revenue dip of about ₹42 crore.
Customer Concentration: A massive 92% of their revenue in 2023 came from injectables alone; any shift in that market hits them hard.
